REGULATORY

Chuikyo Begins Debate on Scope of FY2025 Off-Year Drug Price Revisions

By Ken Yoshino December 5, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) on December 4 kicked off discussions on the product coverage and rules to be applied for the next “off-year” drug price revision slated for FY2025. While payers were in lockstep seeking revisions on…

To read the full story

MHLW Proposes Setting Product Scope for Off-Year Revisions by Category
December 19, 2024

REGULATORY

Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…